Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Export Revenue as % of Total Revenue % ・Standalone data |
|
||||
| Permanent Employees on Roll count ・Standalone data |
|||||
| Related Party Sales as % of Total Revenue % ・Standalone data |
|||||
| Number of Production Batches count ・Standalone data |
|||||
| Number of Products Manufactured count ・Standalone data |
|||||
| Total Dispatched Volume kg ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Results-Delay in Financial Results
- Board approved FY26 audited results on August 25, 2026; typo corrected in approval date.
- Results-Delay in Financial Results
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- Approved audited FY26 results; Q4 profit Rs72.51 lakh, annual profit Rs111.08 lakh, unmodified audit opinion.
-
Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015.
- Board meets on 25 August 2026 to approve audited standalone FY2026 results.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Crisil report notes Rs 25.91 lakh misused, later returned; rights issue deployment delayed.
Business Overview[1]
The Co. manufactures and distributes pharmaceuticals, bulk drugs, chemicals, and pesticides. The company also conducts R&D across the biotechnology, healthcare, and industrial sectors, specializing in the export and import of various chemical formulations.